In a new interview with Vulture, Sufjan Stevens opened up about his health following his 2023 diagnosis with Guillain-Barré ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome ...

The Move GBS Forward campaign highlights a promising new approach to treatment of the disease. Annexon Biosciences CEO Doug ...

A San Antonio woman passionate about teaching special education with the North East Independent School District had to retire ...

Pune: A seven-and-half-year-old boy was discharged from Deenanath Mangeshkar Hospital on May 3 after battling a ...

BENGALURU: The Karnataka High Court appointed the wife of a retired man as his guardian to operate his three savings bank ...

“Our most advanced program, tanruprubart, is approaching filing for the treatment of Guillain-Barré Syndrome (GBS) having consistently demonstrated rapid and sustained functional improvements ...

The Court noted that the petitioner’s husband had been in the ICU for almost nine months and had lost all ability to write or sign any bank document ...

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study ...

022). This interesting study suggests that patients whose IgG levels increase less after treatment of GBS with IVIg have worse outcomes compared with those who have larger increases in IgG.